Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or
retrospective patient cohorts with human epidermal growth factor receptor 2–positive …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …

Highlights•This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours.•The guideline covers clinical and …

Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …

Purpose This guideline provides updated evidence-based recommendations addressing
recent developments in the management of patients with brain metastases, including …

Abstract Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity
in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has …

Brain metastases affect a significant percentage of patients with advanced extracranial
malignancies. Yet, the incidence of brain metastases remains poorly described, largely due …

The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …